Pattern of use of incretin-based drugs in clinical practice

Study type

• Study topic:
  Disease /health condition

  Human medicinal product
• Study type:
  Non-interventional study
• Scope of the study:
  Drug utilisation
• Data collection methods:
  Secondary use of data

Non-interventional study

• Non-interventional study design:
  Other
• Non-interventional study design, other:
  Pharmacoepidemiological study

Study drug and medical condition

• Study drug International non-proprietary name (INN) or common name:
  SITAGLIPTIN

  VILDAGLIPTIN

  SAXAGLIPTIN

  ALOGLIPTIN

  LINAGLIPTIN

  EXENATIDE

  LIRAGLUTIDE

  LIXISENATIDE
• Medical condition to be studied:
  Type 2 diabetes mellitus

Population studied

• Short description of the study population:
  All subjects registered in the administrative databases of Tuscany, Umbria and Caserta between January 1, 2008 and December 31, 2014 who had ≥18 years of age and at least 365 days of look-back period.
• Age groups:
  Adults (18 to < 46 years)

  Adults (46 to < 65 years)

  Adults (65 to < 75 years)

  Adults (75 to < 85 years)

  Adults (85 years and over)
• Estimated number of subjects:
  6000000

Study design details

• Main study objective:
  To describe in greater details the pattern of use of incretin-based drugs in large sample of the Italian general population.
• Data analysis plan:
  The annual incidence and prevalence of use of incretin-based therapies, in the general population will be calculated per each year of the period 2008-2014. The annual percentages of incident and prevalent incretin users on total number of users of antidiabetics will be observed. Annual percentage of new users of GLP-1 analogues, DPP-4 inhibitors and relevant actcive principles belonging to the two groups will be calculated on the total number of new users of incretin-based therapies. Incident incretin users will be described in terms of demographic characteristics, previous antidiabetics treatments and other drug therapies.

Documents

Study results

poster_incretin_Glasgow

Study publications

Roberto G, Barone-Adesi F, Giorgianni F, Pizzimenti V, Ferrajolo C, Tari M, Bar…